Gen-Probe H1N1 flu test
This article was originally published in The Gray Sheet
FDA grants emergency use authorization for Gen-Probe's Prodesse ProFlu-ST flu test, to be used in high-complexity CLIA labs to diagnose H1N1 influenza, firm announces Oct. 29. The reverse transcription polymerase chain reaction (RT-PCR) test employs an algorithm linked to seasonal influenza A/H1 and A/H3 virus test results. Other H1N1 flu tests granted EUAs in recent months include Quest Diagnostic's Simplexa Influenza A H1N1 (2009) and Focus Diagnostics Influenza H1N1 (2009) tests ("1The Gray Sheet" Oct. 26, 2009)
You may also be interested in...
With seven H1N1 diagnostics already authorized for emergency use by FDA, the agency is signaling its interest in promoting additional alternatives with the release of a Nov. 2 guidance document
A second emergency use authorization request is granted to Quest's Focus Diagnostics unit by FDA Oct. 16 for an H1N1 influenza test. This one will allow Quest to market and offer its Simplexa Influenza A H1N1 (2009) test for use on the 3M Integrated Cycler. FDA granted an EUA July 24 to Quest for its Focus Diagnostics Influenza H1N1 (2009) real-time reverse transcription polymerase chain reaction test (1"The Gray Sheet" July 27, 2009). While 3M's Integrated Cycler diagnostic testing system is not FDA cleared or approved, when the Simplexa test is used on the 3M platform, it can provide increased capacity for 2009 H1N1 flu testing to a wide range of CLIA high-complexity laboratories, including hospital labs coping with a surge in testing demand this fall
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.